Immunovia AB (publ) (IMMNOV.ST)
Stockholm · SEK · Healthcare · Diagnostics & Research
SEK 0.0693 (-3.48%) as of
Key statistics
- Market cap
- 46.62M
- Forward P/E
- 0.01
- EPS (TTM)
- -0.1400
- Dividend yield
- 0.00%
- 52-week range
- 0.0600 – 0.3555
- Beta
- 2.73
- Revenue (TTM)
- 1.21M
- Profit margin
- 0.00%
- Analyst target
- SEK 0.43
- Volume
- 4.41M
About Immunovia AB (publ)
Immunovia AB (publ), a diagnostic company, develops and validates blood test for detecting pancreatic cancer in Sweden. It also focuses on the development and commercialization of blood-based testing to detect proteins and antibodies that indicate pancreatic cancer in an individual. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Headquarters
- Lund, Sweden
- Employees
- 18
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.